Skip to content
Review

AI-Driven Precision Medicine in Alzheimer's Disease: Drug Repurposing, Digital Therapeutics and Clinical Decision Support.

Aug 2026 · Current pharmaceutical design · Vol 32 · 0 citations
Medicine

TL;DR

AI's ability to alter AD care opens the door to precision medicine paradigms that use repurposed medications, digital tools and intelligent decision-making to improve patient outcomes.

Abstract

Alzheimer's Disease (AD) is a neurodegenerative disease that causes significant clinical, social, and economic burden worldwide. Despite improvements in understanding its multifaceted pathogenesis, current treatments are mostly symptomatic and ineffective across varied patient populations. To overcome these constraints, AI-driven precision medicine allows tailored risk assessment, treatment selection, and disease monitoring. This review covers AI's role in AD precision medicine, focusing on drug repurposing, digital therapies and clinical decision support systems. Machine and deep learning models are used to predict medication response, integrate heterogeneous data sources such as genomics, transcriptomics, neuroimaging and electronic health records, and uncover pharmacogenomic treatment success factors. The paper covers AIenabled precision pharmacology, including tailored dosing algorithms, adaptive therapeutic monitoring, and adverse drug reaction prediction. Bioinformatics-based target identification, network pharmacology, graphbased AI models, virtual screening, and real-world and clinical data validation are emphasized in AI-driven medication repurposing. AI-powered digital treatments like personalized cognitive training platforms, wearable- derived digital biomarkers, virtual and mixed reality interventions, adherence monitoring, and digital twins for therapy optimization have been discussed. AI-based clinical decision support systems are also thoroughly assessed for clinical value, accuracy, and explainability in disease subtyping, trajectory prediction, and risk stratification in preclinical and prodromal AD. Despite these promises, data heterogeneity, algorithmic bias, legal barriers, and privacy concerns exist. Federated learning enables safe multi-center collaboration and hybrid AI-human approaches, and it represents the future. AI's ability to alter AD care opens the door to precision medicine paradigms that use repurposed medications, digital tools and intelligent decision-making to improve patient outcomes.

View source

Similar papers

Review Aug 2026

Pharmacogenomics and Personalized Medicine: Leveraging AI and Machine Learning for Optimized Therapies

To examine how artificial intelligence (AI) and machine learning (ML) can advance pharmacogenomics and personalized medicine by improving drug-response prediction, treatment selection, dosing, and clinical decision support, while identifying the major barriers to clinical implementation. This narrative review criticall...

Arwa Al Anber · 0 citations
Open access Sep 2026

Discovering repurposable drugs for Alzheimer’s disease and related dementias: target trial emulation using decentralised real-world data

Summary Background Alzheimer’s disease and related dementias (ADRD) affect nearly 6.9 million Americans, with the number expected to triple by 2050, while disease-modifying therapies remain unavailable. Drug repurposing, which identifies new indications for already approved medications, offers a more efficient and cost...

Qiong Wu, Lu Li, Yu-Qing Lei et al. · 0 citations
Review Open access Sep 2026

Machine Learning and Multimodal Biomarker Discovery in Alzheimer’s Disease

This mini-review covers the evolving AD diagnostic and biomarker frameworks, current therapeutic strategies including recently approved anti-amyloid immunotherapies, and advances from contemporary studies employing ML across diverse data streams.

Tariq Tayebi, M. David, M. Tayebi · 0 citations
Review Sep 2026

Artificial Intelligence-Driven Strategies for Predicting, Personalizing, and Optimizing Therapeutic Targets in Inflammatory Bowel Disease.

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, represent chronic relapsing inflammatory disorders characterized by complex interactions among genetic, microbiome-related, immunological, and environmental factors. Although advances in biologics and small-molecule inhibitors have exp...

Priyanka Paul, Ankush Kumar, Rajwinder Kaur et al. · 0 citations
Review Sep 2026

Harnessing Artificial Intelligence to Predict and Overcome Drug Resistance in Breast Cancer: A Translational Approach.

This review discusses how AI can accelerate computational drug discovery, virtual screening (VS), and the repurposing of already-approved medications, and it can also optimize combination therapies through computational simulation.

D. Bhagwat, Sonali A. Chikhalwale, S. Mali et al. · 0 citations
Review Open access Aug 2026

Research Progress in Network Medicine and Artificial Intelligence-Based Prediction of Drug Combination Synergy

Current studies remain constrained by data sparsity, negative-sample bias, insufficient model interpretability and limited prospective validation, so future work should strengthen standardized data integration, mechanism-constrained modeling and joint dose-timing optimization to improve interpretability, generalizabili...

Haoyang Su · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.